LivaNova PLC LIVN
At closeNov 4, 2026, 8:42 AM EST
Pre-market · Nov 4, 8:42 AM ET
- YTD
- +29.86%
- 1 year
- +51.96%
- Market cap
- 4.39B
- Revenue (ttm)
- 1.47B
- Profit margin
- 12.81%
- EPS (ttm)
- 3.38
- Shares out
- 54.93M
- P/E ratio
- 23.64
- Forward P/E
- 17.06
- YTD return
- +29.86%
- 1-year return
- +51.96%
- Volume
- 946.61K
- Avg volume
- 639.97K
- Open
- 80.40
- Previous close
- 80.21
- Day's range
- 79.56 – 81.87
- 52-week range
- 48.82 – 85.76
- Beta
- 0.92
- Analysts
- Buy
- Price target
- 90.55 (+13.3%)
- Earnings date
- Nov 4, 2026
5D +0.30 (+0.37%)
Key statistics
- Enterprise value
- 4.25B
- PEG ratio
- 0.93
- Price / sales
- 2.98
- Price / book
- 3.32
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 10.80%
- Free cash flow
- 59.87M
- Total cash
- 516.62M
- Total debt
- 351.95M
- Return on equity
- 15.40%
- Short % of float
- 12.92%
- 50-day average
- 78.52
- 200-day average
- 72.99
Analyst view
Consensus: buy
- Target (low)
- 75.00
- Target (mean)
- 90.55
- Target (high)
- 105.00
- Strong buy3
- Buy6
- Hold2
- Sell0
- Strong sell0
Next earnings
Nov 4, 2026
Expected Nov 4, 2026. Consensus EPS estimate 1.06.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 4, 2026 | Sep 30, 2026 | 1.06 | — | — | — |
| Aug 5, 2026 | Jun 30, 2026 | 1.09 | 1.26 | +0.17 | +15.60% |
| May 6, 2026 | Mar 31, 2026 | 0.85 | 0.98 | +0.13 | +15.29% |
| Feb 25, 2026 | Dec 31, 2025 | 0.80 | 0.86 | +0.06 | +7.50% |
| Nov 5, 2025 | Sep 30, 2025 | 0.919 | 1.11 | +0.19 | +20.78% |
| Aug 6, 2025 | Jun 30, 2025 | 0.84 | 1.05 | +0.21 | +25.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 7, 2026 | Barclays | init | — | Overweight |
| Sep 2, 2026 | Piper Sandler | reit | Overweight | Overweight |
| Aug 5, 2026 | Needham | main | Buy | Buy |
| Jul 15, 2026 | Mizuho | main | Outperform | Outperform |
| Jul 1, 2026 | Freedom Capital Markets | init | — | Hold |
| Jun 22, 2026 | Keybanc | main | Overweight | Overweight |
About LivaNova PLC
LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories, as well as services related products. The Neuromodulation segment offers VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals; and devices that deliver neuromodulation therapy for treating drug-resistant epilepsy and depression. This segment also includes the development and clinical testing of aura6000 system for treating obstructive sleep apnea. It serves perfusionists, neurologists, neurosurgeons, hospitals, other healthcare professionals and medical institutions, and healthcare providers. The company sells its medical devices through direct sales representatives, agents, and independent distributors in the United States, the United Kingdom, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switzerland, Austria, Norway, Portugal, Finland, Denmark, and internationally. LivaNova PLC was incorporated in 2015 and is headquartered in Gloucester, the United Kingdom.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United Kingdom
- Website
- livanova.com
News
LivaNova Raises FY2026 Adj EPS Guidance from $4.30-$4.40 to $4.40-$4.50 vs $4.37 Est; Raises FY2026 Sales Guidance from $1.499B-$1.513B to $1.513B-$1.527B vs $1.522B Est 
LivaNova Q3 Adj. EPS $1.23 Beats $1.06 Estimate, Sales $393.100M Beat $381.067M Estimate 
LivaNova Reports Third-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance 
LivaNova Publishes Results In Neuromodulation: Technology At The Neural Interface Regarding Its CORE-VNS Trial Of Its VNS Therapy Devices - Barclays Initiates Coverage On LivaNova with Overweight Rating, Announces Price Target of $105
- Piper Sandler Reiterates Overweight on LivaNova, Raises Price Target to $90
- Needham Maintains Buy on LivaNova, Raises Price Target to $93
LivaNova Raises FY2026 Adj EPS Guidance from $4.20-$4.30 to $4.30-$4.40 vs $4.25 Est; Raises FY2026 Sales Guidance from $1.445B-$1.458B to $1.499B-$1.513B vs $1.507B Est 
LivaNova Q2 Adj. EPS $1.26 Beats $1.10 Estimate, Sales $390.600M Beat $380.758M Estimate - Mizuho Maintains Outperform on LivaNova, Raises Price Target to $95
Your note
Sign in to keep a note on LIVN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BARRY JAMES CHRISTOPHER | Director | Conversion of Exercise of derivative security | Jun 14, 2026 | 7,918 |
| BOLTON STEPHANIE | Officer | Conversion of Exercise of derivative security | Mar 29, 2026 | 22,189 |
| ENXING SENG STACY | Director | Conversion of Exercise of derivative security | Jun 14, 2026 | 15,307 |
| KOZY WILLIAM A | Director | Conversion of Exercise of derivative security | Jun 14, 2026 | 37,566 |
| MAKATSARIA VLADIMIR A. | Chief Executive Officer | Conversion of Exercise of derivative security | Mar 29, 2026 | 14,167 |
| O'KANE SHARON | Director | Conversion of Exercise of derivative security | Jun 12, 2025 | 11,304 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 13.73% | 7,565,342 | 604.47M | Jun 29, 2026 |
| Primecap Management Company | 7.57% | 4,168,377 | 333.05M | Jun 29, 2026 |
| FMR, LLC | 5.71% | 3,147,068 | 251.45M | Jun 29, 2026 |
| Hood River Capital Management LLC | 4.66% | 2,565,477 | 204.98M | Jun 29, 2026 |
| AQR Capital Management, LLC | 4.28% | 2,356,191 | 188.26M | Jun 29, 2026 |
| Invesco Ltd. | 4.06% | 2,237,319 | 178.76M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Mid-Cap ETF | 3.56% | 1,963,642 | 156.89M | Sep 29, 2026 |
| VANGUARD HORIZON FUNDS-Vanguard Capital Opportunity Fund | 3.45% | 1,902,700 | 152.03M | Jun 29, 2026 |
| AIM Sector Funds (Invesco Sector Funds)-Invesco Small Cap Value Fund | 3.05% | 1,679,556 | 134.20M | Jul 30, 2026 |
| American Century ETF Trust-Avantis U.S. Small Cap Value ETF | 2.92% | 1,607,363 | 128.43M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.63% | 1,450,682 | 115.91M | Sep 29, 2026 |
| Artisan Partners Funds Inc.-Artisan International Small-Mid Fund | 2.49% | 1,374,576 | 109.83M | Jun 29, 2026 |